Cagrilintide is a novel, long acting peptide designed to target multiple receptors involved in appetite regulation and energy balance. Unlike traditional weight loss medications that often target a single pathway, cagrilintide acts as CagrilintideSemaglutide in Adults with Overweight or Obesity and Type 2 Diabetes New England Journal of Medicine Research Peptide Spotlight: Calgri (Cagrilintide) is here! The long acting amylin analog that's blowing up in metabolic research. This powerhouse mimics your body's natural satiety hormone, helping dial down appetite and support Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Novo Nordisk's Cagrilintide shows promising weight loss in REDEFINE 1 sub analysis, unveiled at EASD 2025 Pharmacally REDEFINE 1 Trial Finds CagrilintideSemaglutide Combo Delivers Over 20% Weight Loss in Majority of Patients Applied Clinical Trials Online